Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled study of epeleuton in type 2 diabetes with complications
2020-002911-23Phase 2Completed
- Sponsor
- Afimmune
- Start
- Aug 2020
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and diabetes complications comparing Epeleuton arm with Placebo arm (2 arms). Primary endpoints: Pharmacodynamic objective and Safety objective. Started Aug 2020; status: completed.
02
Drugs
epeleuton
03
Conditions
type 2 diabetes mellitus (T2DM)diabetes complications
Beyond the preview
Go deeper on 2020-002911-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002911-23.